Cardiac Arrest Treatment Market Estimated to Experience a Hike in Growth by 2027

Comments · 254 Views

Cardiac Arrest Treatment market is estimated to attain a valuation of US$26 bn by the end of 2027

The cardiac arrest treatment market focuses on addressing the critical medical emergency of sudden cardiac arrest (SCA), a life-threatening condition characterized by the abrupt cessation of cardiac activity. SCA requires immediate intervention to restore cardiac function and circulation, with timely resuscitation efforts crucial for improving patient outcomes. The market encompasses a range of therapeutic interventions aimed at resuscitation, post-resuscitation care, and prevention of recurrent cardiac events.

Cardiac Arrest Treatment market is estimated to attain a valuation of US$26 bn by the end of 2027, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 14.7% during the forecast period, 2019-2027

Get a Sample Copy of the Cardiac Arrest Treatment Market Research Report –https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=61416

The significant players operating in the global Cardiac Arrest Treatment market are- Cell Signaling Technology, Inc., Terumo Corporation, GE Healthcare, STEMCELL Technologies, Takara Bio, Inc., Bio-Techne (R&D Systems), Octane Biotech, Inc., Dickinson and Company, Merck Millipore (Merck KGaA), Corning Incorporated, Eppendorf AG, PeproTech, Inc., Danaher Corporation (Pall Corporation), Lonza Group, Becton

Key Drivers:

  1. High Mortality Rate: Sudden cardiac arrest is a leading cause of death globally, with a high mortality rate if not promptly treated. The urgent need for effective resuscitation strategies and advanced critical care interventions drives the demand for innovative treatments and technologies to improve survival and neurological outcomes in patients experiencing cardiac arrest.
  2. Advancements in Resuscitation Science: Ongoing advancements in resuscitation science, including updates to CPR guidelines, improvements in defibrillation technology, and the development of novel therapeutic interventions such as targeted temperature management (TTM), extracorporeal membrane oxygenation (ECMO), and mechanical circulatory support devices, have transformed the field of cardiac arrest treatment and improved survival rates.
  3. Public Awareness and Training: Public awareness campaigns, widespread CPR training initiatives, and the availability of automated external defibrillators (AEDs) in public places have contributed to early recognition of cardiac arrest, bystander-initiated CPR, and prompt defibrillation, resulting in improved outcomes and increased survival rates in communities with high rates of bystander intervention.
  4. Focus on Post-Resuscitation Care: Recognizing the importance of post-resuscitation care in determining long-term outcomes after cardiac arrest, there is growing emphasis on optimizing hemodynamic stability, managing systemic complications such as hypotension and hypoxemia, and implementing neuroprotective strategies to minimize brain injury and improve neurological recovery in survivors of cardiac arrest.

Recent Developments:

  1. Extracorporeal Life Support: Extracorporeal membrane oxygenation (ECMO) and other forms of extracorporeal life support offer advanced cardiopulmonary support for patients with refractory cardiac arrest, providing temporary circulatory and respiratory support to sustain vital organ function while underlying cardiac pathology is addressed.
  2. Targeted Temperature Management: Targeted temperature management (TTM) aims to optimize neurological outcomes after cardiac arrest by maintaining strict temperature control and preventing hyperthermia or hypothermia, which can exacerbate brain injury. TTM has become a standard component of post-resuscitation care in many hospitals and critical care settings.
  3. Advanced Cardiac Monitoring: Continuous cardiac monitoring, including invasive hemodynamic monitoring, echocardiography, and advanced electrophysiological studies, plays a crucial role in guiding resuscitation efforts, identifying reversible causes of cardiac arrest, and optimizing cardiovascular support in patients with hemodynamic instability or shock.
  4. Neuroprotective Strategies: Emerging neuroprotective interventions, such as pharmacological agents targeting neuroinflammation and oxidative stress, as well as neuromodulation techniques such as therapeutic hypothermia and transcranial magnetic stimulation, hold promise for improving neurological outcomes and reducing disability in survivors of cardiac arrest.

Market Segmentation –

Treatment
  • Drugs
    • Vasopressors
    • Anti-arrhythmic Drugs
    • Anticholinergic Drugs
    • Corticosteroids
    • Fibrinolytic Drugs
    • Beta Blockers
    • Others (sodium bicarbonate, crystalloids, colloids, etc.)
  • Medical Devices
    • Defibrillators
    • Cardiac Resynchronization Therapy (CRT)
    • Others
Sales Channel
  • Hospitals
  • Independent Pharmacies
  • Others

This Report lets you identify the opportunities in Cardiac Arrest Treatment Market by means of a region:

  • North America (the United States, Canada, and Mexico)
  • Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
  • Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
  • South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

Contact Us

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Comments